# (19) World Intellectual Property Organization

International Bureau





PCT

#### (43) International Publication Date 9 March 2006 (09.03.2006)

(51) International Patent Classification: *A61B 17/00* (2006.01)

(21) International Application Number:

PCT/US2005/028660

(22) International Filing Date: 11 August 2005 (11.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10/928,744 27 August 2004 (27.08.2004) US

(71) Applicant (for all designated States except US): ACCESS-CLOSURE, INC. [US/US]; 2460 Embarcadero Way, Palo Alto, CA 94303 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): KHANNA, Puneet, K. [IN/US]; 72415 Tanglewood Lane, Rancho Mirage, CA 92270 (US). KHOSRAVI, Farhad [US/US]; 25698 Elena Road, Los Altos Hills, CA 94022 (US).
- (74) Agent: BURSE, David, T.; Bingham McCutchen LLP, Three Embarcadero Center, Suite 1800, San Francisco, CA 94111-4067 (US).

(10) International Publication Number WO 2006/026116 A1


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: APPARATUS FOR FACILITATING HEMOSTASIS WITHIN A VASCULAR PUNCTURE



M Company of the control of the cont

(57) Abstract: Apparatus for sealing a puncture communicating with a blood vessel includes a bioabsorbable sealing member secured to one end of a filament or other retaining member. The sealing member is delivered through the puncture into the vessel, and retracted against the wall of the vessel to provide temporary hemostasis. The sealing member is rapidly absorbed after exposure within the vessel, e.g., to an aqueous or heated physiological environment (e.g., exposure to blood or body temperature), immediately or shortly after completing a medical procedure via the puncture, e.g., within the time period that the patient is ambulatory.

# APPARATUS FOR FACILITATING HEMOSTASIS WITHIN A VASCULAR PUNCTURE

#### FIELD OF THE INVENTION

5

10

15

20

25

This invention relates generally to apparatus for sealing punctures in a body, and more particularly, to apparatus for delivering a fast-dissolving sealing device into a puncture extending from a patient's skin to a blood vessel or other body lumen to provide temporary hemostasis.

## BACKGROUND

 $(x_0, \dots, x_n) = x_0 + \dots + x_n = x_n + \dots + x_n = 0$ 

Apparatus are known for accessing a patient's vasculature percutaneously, e.g., to perform a procedure within the vasculature, and for sealing the puncture that results after completing the procedure. For example, a hollow needle may be inserted through a patient's skin and overlying tissue into a blood vessel. A guide wire may be passed through the needle lumen into the blood vessel, whereupon the needle may be removed. An introducer sheath may then be advanced over the guide wire into the vessel, e.g., in conjunction with or subsequent to one or more dilators.

A catheter or other device may be advanced through the introducer sheath and over the guide wire into a position for performing a medical procedure. Thus, the introducer sheath may facilitate introducing various devices into the vessel, while minimizing trauma to the vessel wall and/or minimizing blood loss. Upon completing the procedure, the device(s) and

introducer sheath may be removed, leaving a puncture extending between the skin and the vessel wall.

To seal the puncture, external pressure may be applied to the overlying tissue, e.g., manually and/or using sandbags, until hemostasis occurs. This procedure, however, may be time consuming and expensive, requiring as much as an hour of a medical professional's time. It is also uncomfortable for the patient, and may require the patient to remain immobilized in the operating room, catheter lab, or holding area. In addition, a risk of hematoma exists from bleeding before hemostasis occurs.

5

10

15

20

Various apparatus have been suggested for sealing a percutaneous puncture instead of using external pressure. For example, U.S. Patent No. 5,108,421 issued to Fowler discloses a plug that may be delivered into a puncture through tissue. In one embodiment, a catheter is inserted through the puncture into the blood vessel. A balloon on the catheter is expanded and retracted until the balloon is disposed adjacent the puncture at the wall of the vessel. The plug may be advanced into the puncture until the plug contacts the balloon. Once the plug is positioned within the puncture, the balloon may be deflated and withdrawn, leaving the plug therein to expand and seal the puncture and/or to promote hemostasis.

Alternatively, U.S. Patent No. 5,222,974 issued to Kensey et al. describes a system for sealing a percutaneous puncture in an artery. The system includes a sealing member including

a resorbable plug, a rigid resorbable anchor member, and resorbable positioning member in the form of a filament. The disclosed sealing member is designed to resorb completely, e.g., within sixty to ninety (60-90) days.

5

10

15

20

U.S. Patent No. 6,663,655 issued to Ginn et al. discloses a two-piece plug device for sealing a passage through tissue. The device includes a plug member and a sealing member disposed within a lumen of the plug member. The device is delivered into a puncture proximate to a vessel communicating with the puncture. The plug member and sealing member are made of a bioabsorbable material and may remain within the body until both components are absorbed.

U.S. Patent No. 5,916,236 issued to Muijs Van de Moer et al. discloses an occlusion assembly that includes a flexible sheet attached to one end of a thread, and a retaining ring slidable along the thread towards the sheet. The sheet is folded, delivered via a sheath through a puncture into a blood vessel, and allowed to unfold within the vessel. The thread is pulled to direct the sheet against the wall of the vessel, whereupon the retaining ring is advanced down the thread to secure the sheet against the wall. The sheet, thread, and retaining ring are made of bioabsorbable material such that they disappear after a few weeks.

U.S. Patent No. 4,890,612 issued to Kensey discloses a three-component closure device that includes a holding member or toggle, a filament, and a cylindrical plug made of

bioabsorbable materials that is absorbed in approximately, forty five days, ninety days, and ten days, respectively. The closure device is delivered through a puncture into a blood vessel via a sheath, whereupon the filament is retracted to pull the toggle against the wall of the vessel with the plug within the puncture. The closure device remains in place until absorbed by the patient's body.

5

10

15

20

25

One of the disadvantages with these closure devices is that it may be difficult to position them properly with respect to the vessel, which may be significant since it is generally undesirable to expose collagen material to the bloodstream where it may float downstream and cause an embolism. In addition, these closure devices take a relatively long period of time to resorb and/or dissolve within the body (i.e., ten days or more). This is particularly undesirable for the portion of the device that is disposed within the blood vessel, because of the risk of a piece of the closure device breaking free and causing an embolism or other damage downstream of the puncture site.

Even when non-collagen materials are used for the portion of a closure device residing within a blood vessel, however, it may be desirable to minimize the amount of time the intravascular portion of the device is present within the vessel. Of course, if the device is absorbed too rapidly, it may adversely affect effective hemostasis of the puncture without risk of hematoma or other complications.

#### SUMMARY OF THE INVENTION

This invention is directed to apparatus for providing temporary or permanent hemostasis within a puncture extending through tissue, e.g., to a blood vessel or other body lumen, and/or to apparatus and methods for delivering a sealing device through a percutaneous puncture into a vessel or other body lumen that includes an intravascular component that is substantially absorbed during or shortly upon completing a procedure via the puncture.

5

10

15

20

25

In accordance with one embodiment, a device for sealing a puncture extending through tissue into a body lumen includes a filament or other elongate member, and a sealing member on a distal end of the elongate member formed from a bioabsorbable material that may be substantially absorbed by the body within not more than about twenty four (24) hours of exposure to an aqueous physiological environment, e.g., to blood or other fluid within the body lumen. In other embodiments, the sealing member may be substantially absorbed within not more than about twelve (12) hours, three (3) hours, one (1) hour, or even within not more than about thirty (30) minutes of exposure to an aqueous physiological environment within the body lumen. The retaining member may be formed from either a bioabsorbable or non-bioabsorbable material. Optionally, the device may also include extravascular sealing material deliverable within the puncture around the elongate member,

e.g., a plug, a bolus of liquid sealing material, and the like.

5

10

15

25

In another embodiment, a device for sealing a puncture extending through tissue to a body lumen includes a filament or other elongate member formed from a first material, a sealing member formed from a second bioabsorbable material on a distal end of the elongate member, and extravascular sealing material formed from a third bioabsorbable material, the extravascular material being deliverable into the puncture around the elongate member. In one embodiment, the second bioabsorbable material may be absorbed at a faster rate compared to the third bioabsorbable material when exposed to an aqueous physiological environment, e.g., to blood or other fluid from the body lumen. Optionally, the first material is also bioabsorbable, e.g., at a slower rate compared to the second bioabsorbable material when exposed to an aqueous physiological environment.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 FIG. 1 is an exploded side view of an embodiment of an apparatus for facilitating hemostasis of a puncture extending through tissue.

FIGS. 2A-2C are cross-sectional views of a patient's body, illustrating use of an apparatus according to the invention for sealing a puncture extending through tissue to a blood vessel.

FIGS. 3A and 3B are cross-sectional views of a patient's body, showing another apparatus according to the invention for sealing a puncture extending through tissue to a blood vessel.

FIG. 4 is a cross-sectional view of a patient's body, showing a system for sealing a puncture extending through tissue to a blood vessel that includes an intravascular and extravascular sealing components.

FIG. 5 is a cross-sectional view of a patient's body, showing yet another device according to the invention for sealing a puncture extending through tissue to a blood vessel.

FIG. 6 is a cross-sectional view of a patient's body, showing still another embodiment of an apparatus according to the invention for sealing a puncture extending through tissue to a blood vessel.

15

20

25

10

5

DETAILED DESCRIPTION OF THE ILLUSTRATED EMBODIMENTS

Turning to the drawings, FIG. 1 illustrates an exemplary embodiment of a closure device 2 and an apparatus 1 for facilitating temporary or permanent hemostasis of a puncture extending through tissue using the closure device 2.

Generally, the apparatus 1 includes a delivery sheath 20, and a plunger, catheter, or other pusher member 30 for deploying the closure device 2 from the delivery sheath 20. Optionally, the apparatus 1 may include a source of sealing material 40, e.g., that may be delivered via the delivery sheath 20, as described further below.

The closure device 2 generally includes a filament or other retaining member 12 including a proximal end 12a and a distal end 12b, and a bioabsorbable sealing member 10 on the distal end 12b. The filament 12 may be a solid or hollow elongate body, e.g., a suture, string, wire, tube, and the like, e.q., having a diameter, thickness, or other crosssectional dimension of not more than about 0.90 mm. embodiment, the filament 12 may be a bioabsorbable suture, e.g., made from poly(qlycolic-co-lactic) acid, poly (glycolic acid), and the like. In this embodiment, the retaining member 12 may be made from material that may be absorbed over a longer period of time compared to the sealing member 10. For example, the filament 12 may be absorbed over a period of at least about twenty-four (24) hours after exposure to an aqueous environment, and may take as long as days, weeks, or even months to absorb completely. Alternatively, the filament 12 may be formed from a biocompatible, nonbioabsorbable material, such as nylon, Teflon, catgut, silk, polypropylene, and the like.

5

10

15

20

25

The filament 12 may be substantially flexible, i.e., having little or no column strength. Alternatively, the filament 12 may have sufficient column strength such that the distal end 12b carrying the sealing member 10 may be advanced distally, e.g., from the delivery sheath 20, by pushing on the proximal end 12a of the filament 12, as described further below. The filament 12 should have sufficient strength in

tension to allow the sealing member 10 to be pulled through a puncture against a wall of a blood vessel or other body lumen, e.g., to substantially seal the puncture from the vessel without the filament 12 breaking and/or separating from the sealing member 10.

5

10

15

20

25

Optionally, particularly if the filament 12 is not bioabsorbable, an exterior surface of the filament 12 may include a lubricious coating or other material, for example, to facilitate withdrawing the filament 12 through a puncture, e.g., after the puncture has been at least partially filled with sealing material around the filament 12, as explained further below.

As shown, the sealing member 10 is affixed to the distal end 12b of the filament 12 at a fixation or toggle location 16, e.g., at or near the center or midpoint of the sealing member 10. The filament 12 may be at least partially embedded within the sealing member 10 at the fixation location 16 and/or may extend at least partially around to secure the sealing member 10 to the distal end 12b. For example, the distal end 12b may include a loop (not shown) that may be secured around a portion of the sealing member 10 and/or may extend through one or more openings (also not shown) through the sealing member 10. In addition or alternatively, an adhesive or other material (not shown) may be used to attach the distal end 12b to the sealing member 10.

The sealing member 10 may be a body generally defining a plane, i.e., having a thickness or other minor dimension that is substantially smaller than its width, diameter, or other major dimension. For example, as shown, the sealing member 10 may be generally disk-shaped, having a circular, square, polygonal, or other shape generally within a plane and defining upper and lower surfaces 10a, 10b. The generally upper and lower surfaces 10a, 10b may be substantially planar, concave and/or convex (not shown).

5

10

15

20

25

The sealing member 10 may be formed from a rapidly absorbing, biocompatible material. As used herein, "rapidly absorbing" means material that is absorbed by any physical process (e.g., dissolving, melting, or the like) within a relatively short period of time, e.g., not more than about twenty four (24) hours, e.g., upon exposure to an aqueous physiological environment. An example of an aqueous physiological environment is a location within a patient's body exposed to blood or other bodily fluids, such as an interior of a blood vessel or other organ.

In other embodiments, the sealing member 10 may be substantially absorbed within about twelve (12) hours of exposure to an aqueous physiological environment, within about three (3) hours, about one (1) hour, or even less than about thirty (30) minutes of exposure to an aqueous physiological environment. In this regard, the intravascular aspect of the sealing device 2, namely, the sealing member 10, may be

substantially absorbed before the patient becomes ambulatory, i.e., during or immediately following a procedure performed via the puncture. Thus, the amount of time that the sealing member 10 remains intact within the patient's body may be minimized compared to known closure devices that may be absorbed by a patient's body over days, weeks, or months.

5

10

15

20

25

Exemplary materials for the sealing member 10 may carbohydrate (sugar) or salt-based materials, e.g., that rapidly dissolve in the presence of an aqueous environment, e.g., blood or other bodily fluids. In addition or alternatively, the sealing member 10 may be formed from a material that rapidly melts due to the increased temperature within a patient's body, e.g., when exposed to temperatures of about thirty seven degrees Celsius (37 oC) or more.

In one embodiment, the sealing member 10 may be preformed into a shape that prevents the sealing member 10 from
being pulled easily through an arteriotomy or other opening
through a wall of a blood vessel or other body lumen into a
puncture (not shown). Further, the shape of the sealing
member 10 may aid in substantially sealing such a puncture
from the vessel, e.g., to provide temporary hemostasis.

Optionally, the sealing member 10 may include structural
features (e.g., structural reinforcement elements, shaped
sealing surfaces, and the like, not shown) that may aid in
preventing the sealing member 10 from being dislodged through
an arteriotomy or other opening once deployed.

The sealing member 10 may be substantially rigid, i.e., fixed in a shape, such as an elongate foot, plate, sheet, a generally disk-shape, or other configuration. Alternatively, the sealing member 10 may be semi-rigid, i.e., such that the shape of the sealing member 10 may conform at least partially to contacted anatomy, e.g., assuming a curved shape conforming to a wall of a vessel or other body lumen when directed against the wall.

5

10

15

20

25

In a further alternative, the sealing member 10 may be substantially flexible, i.e., capable of being deformed into a contracted condition, e.g., to facilitate loading within the delivery sheath 20, and expandable into an enlarged condition, e.g., a generally disk-shaped configuration, when deployed from the delivery sheath 20 and/or when free from outside stresses. For example, the sealing member 10 may be rolled into a generally tubular shape to facilitate loading into the delivery sheath 20, may be compressed or deflected into a lower profile contracted condition, and the like.

With continued reference to FIG. 1, the delivery sheath 20 may be a substantially rigid, semi-rigid, and/or flexible tubular body, including a proximal end 22, a distal end 24 having a size and shape for insertion into a puncture, and a lumen 26 extending therebetween. The distal end 24 may be tapered and/or may include a substantially atraumatic tip 28 to facilitate advancement through a puncture. The delivery sheath 20 may include a handle (not shown), and/or one or more

seals, e.g., a hemostatic seal (also not shown), on the proximal end 22. The closure device 2 may be carried by the delivery sheath 20 such that the sealing member 10 is disposed within the lumen 26 proximate to the distal end 24. The lumen 26 may be sized such that the plug device 2 is slidable therein, e.g., able to traverse distally from the delivery sheath 20 during delivery, as described further below. Optionally, the delivery sheath 20 may include a lubricious coating or other material (not shown) to facilitate sliding the sealing member 10 along the lumen 26, e.g., during deployment.

The pusher member 30 may be an elongate member, e.g., a plunger, catheter, and the like, including a proximal end 32, and a distal end 34 having a size for slidable insertion into and/or movement within the lumen 26 of the delivery sheath 20. The distal end 34 of the pusher member 30 may be substantially blunt or otherwise shaped to facilitate contacting and/or pushing the sealing member 10 within the delivery sheath 20, as described further below. The pusher member 30 may be substantially rigid, semi-rigid, and/or substantially flexible, having sufficient column strength to allow movement of the delivery sheath 20 relative to the sealing member 10 without buckling. The pusher member 30 may also include a lumen 36 extending between the proximal end and the distal end 34, e.g., to accommodate the filament 12 of the closure device 2 and/or a guidewire (not shown) therethrough.

Optionally, as shown in FIG. 1, the apparatus 1 may include a source of sealing material, e.g., syringe assembly 40, for delivering liquid hydrogel precursors or other sealing material 99 into a puncture, e.g., to provide an extravascular sealing component in addition to the intravascular sealing member 10. In one embodiment, the syringe assembly 40 may include a pair of syringes 42 that include two components of a sealing compound therein, a "Y" fitting 44 connected to outlets 46 of the syringes 42, and tubing 52 connectable between the "Y" fitting 44 and a side port 23 on the proximal end 22 of the delivery sheath 20. A plunger assembly 48 may be slidable into the syringes 42 to cause the components therein to be delivered through the outlets 46.

5

10

15

20

25

In one embodiment, the plunger assembly 48 may include a pair of plungers 50 that are coupled to one another yet are received in respective syringes 42. Thus, both plungers 50 may be manually depressed substantially simultaneously to deliver the components in the syringes 42 out together.

Alternatively, an auto-injection device may be provided for delivering the components from the syringes 42, such as that disclosed in U.S. patent application publication No. 2004 - 0267308.

In one embodiment, a liquid precursor polymer compound is provided in each syringe 42 of the syringe assembly 40 that, when mixed together, may be activated to form a hydrogel, such as a poly(ethylene glycol)-based (PEG) multiple component

hydrogel. Additional information on hydrogels and systems for delivering them are disclosed in U.S. Patent Nos. 6,152,943, 6,165,201, 6,179,862, 6,514,534, 6,379,373, and 6,703,047, and in patent applications Publication Nos. 2002-0106409, 2003-0012734, and 2002-0114775.

5

10

15

20

As shown in FIG. 4, the extravascular sealing material 99 may be delivered into a puncture 90 around the filament 12. If the filament 12 is bioabsorbable, the sealing material 99 may at least partially adhere to the filament 12, e.g., to enhance securing the sealing member 10 against the wall of the vessel 94, as described further below. Alternatively, if the filament 12 is to be removed, an exterior surface of the filament 12 may include a lubricious coating or other coating to facilitate pulling the filament 12 through the sealing material 99.

The sealing material 99 may be formed from other bioabsorbable and/or biocompatible material. Similar to the filament 12, the sealing material 99 may be absorbed over a longer period of time compared to the sealing member 10. In exemplary embodiments, the sealing material 99 may be absorbed over a period of time of not less than about twenty-four (24) hours after exposure to an aqueous environment, e.g., in not less than about seven to fourteen (7-14) days.

For example, the sealing material 99 may be formed from 25 biologic-based material, such as collagen, fibrin, carboxymethylcellulose, oxidized cellulose, alginates,

gelatin, or other protein-based material, and/or synthetic materials, such as polyglycolic acids (PGA's), polyactides (PLA's), and the like. The sealing material 99 may be formed into a discernable structure such as a plug, and the like.

5

10

15

20

Turning to FIGS. 2A-2C, an exemplary procedure for delivering the sealing device 2, into a puncture 90 extending through tissue 96 and to a blood vessel or other body lumen 94. Generally, the puncture 90 extends from a patient's skin 92 through intervening tissue 96, e.g., to a body lumen 94 is shown for purposes of illustration. In an exemplary embodiment, the puncture 90 may be a percutaneous puncture communicating with a blood vessel 94, such as a femoral artery, carotid artery, and the like.

The puncture 90 may be created using known procedures, e.g., using a needle, guidewire, one or more dilators, and the like (not shown). An introducer sheath (also not shown) may be advanced through the puncture 90 into the vessel 94, e.g., to provide access into the vessel 90 for one or more instruments, and/or allow one or more diagnostic and/or interventional procedures to be performed via the vessel 90, as is known in the art. Upon completing the procedure(s) via the vessel 94, any instruments and/or the introducer sheath (not shown) may be removed from the puncture 90.

Turning to FIG. 2A, an embodiment of the apparatus 1 is
shown in which a sealing member 10 of a closure device 2 is
loaded into a lumen 26 of a delivery sheath 20 in a contracted

condition. In FIG. 2A, the pusher member 30 (described above and shown in FIG. 1) has been omitted for convenience. As shown, the sealing member 10 may have its outer edges folded inwardly to reduce the profile of the sealing member, and the outer edges may be constrained within the delivery sheath 20. The pusher member 30 may be disposed within the lumen 26 with its distal end 34 adjacent the sealing member 10. The apparatus 1 may be inserted into the puncture 90 and advanced distally until the distal end 24 of the delivery sheath 20 is disposed adjacent the vessel 94 or even enters the vessel 94.

5

10

15

20

25

Turning to FIG. 2B, the pusher member 30 may be advanced distally, e.g., while maintaining the delivery sheath 20 substantially stationary with the distal end 24 within the vessel 90, to deploy the sealing member 10 within the vessel 94. As shown, when the sealing member 10 exits from the distal end 24 of the delivery sheath 20, the sealing member 10 may resiliently return from the contracted condition towards an enlarged condition, e.g., in the shape of a generally planar disk, plate, sheet, or other relaxed state.

Alternatively, if the filament 12 is pushable from the proximal end 12a (i.e., having sufficient column strength), the proximal end 12a of the filament 12 may be directed distally into the delivery sheath 20 to advance the distal end 12b and the sealing member 10 out of the delivery sheath 20 into the vessel 94. In this alternative, it may be possible to eliminate the pusher member 30 completely. In addition,

the delivery sheath 20 may include a lubricious coating or other material (not shown) to facilitate sliding the sealing member 10 out of the distal end 24 of the delivery sheath 20.

Turning to FIG. 2C, the filament 12 may then be drawn proximally to retract the closure device 2 at least partially through the puncture 90, e.g., until the sealing member 10 is directed into contact with the wall of the vessel 94. The delivery sheath 20 may also be at least partially retracted, e.g., if the distal end 24 is advanced into the vessel 94 before or during deployment of the sealing member 10.

5

10

15

20

25

Turning to FIGS. 3A and 3B, in another embodiment, the closure device 2' may include a sealing member 10' attached to a distal end 12b' of a filament or other retaining member 12' to provide a toggle-type device. In this embodiment, the filament 12' may be secured to the sealing member 10' at a fixation location 16,' e.g., located in the middle or center of the sealing member 10.' The sealing member 10' may be disposed within the delivery sheath 20 such that its longitudinal axis or major dimension is disposed axially within the lumen 26 of the delivery sheath 20, as shown in FIG. 3A.

When the toggle-type sealing member 10' is deployed from the delivery sheath 20 and/or within the vessel 94, the sealing member 10 may orient itself within the blood vessel 94 with its longitudinal axis or major dimension disposed transversely to the longitudinal axis of the delivery sheath

20, e.g., along a length of the vessel 94, as shown in FIG.

3B. The sealing member 10' may then be directed against the wall of the vessel 94 by pulling the filament 12' proximally from the puncture 90. Although a width or minor dimension of the sealing member 10' may be less than a width of the arteriotomy or other opening in the wall of the vessel 94, the sealing member 10' may facilitate hemostasis. For example, the sealing member 10' may compress the wall of the vessel 94 and/or otherwise at least partially occlude the opening to substantially seal the puncture 90 from the vessel 94.

5

10

15

20

25

Turning to FIG. 5, in one embodiment, the sealing member 10 (or alternatively another sealing member, such as the sealing member 10' of FIG. 3B) may be retained against the wall of the vessel 94, e.g., to substantially seal the puncture 90 from the vessel 94. Thus, the sealing member 10 may enhance hemostasis, preventing blood or other fluid within the vessel 94 from leaking into the puncture 90. The sealing member 10 may be absorbed after sufficient time for the tissue 96 surrounding the puncture 90 may at least partially occlude the puncture 90, e.g., by coagulation of blood or other mechanisms.

Optionally, external pressure may be applied to the patient's skin 92 above the puncture 90 to further enhance hemostasis. In addition or alternatively, the proximal end 12a of the filament 12 may be secured relative to the patient, e.g., by taping, strapping, adhering, or otherwise securing

the proximal end 12a to the patient's skin 92 adjacent the puncture 90. The proximal end 12a may be secured at a location that ensures that the filament 12 remains under sufficient tension to maintain the sealing member 10 in place against the wall of the vessel 94, e.g., to substantially seal the puncture 90 from the vessel 94.

Alternatively, as shown in FIG. 6, the delivery device 20 may be used to deliver sealing material 99 into the puncture proximal to the sealing member 10. As described above with reference to FIG. 1, the delivery sheath 20 may include a side port 23 coupled to tubing 52 which, in turn, is coupled to syringe assembly 40. The side port 23 may communicate with the lumen 26 of the delivery sheath 20 such that, when two hydrogel precursors within the syringes 42 are directed out the outlets 46, they mix in the "Y" fitting 44, initiating the hydrogel reaction, and pass through the tubing 52, side port 23, lumen 26, and out the distal end 24 of the delivery sheath 20 into the puncture 90.

10

15

optionally, the delivery sheath 20 may be withdrawn
proximally as the sealing material 99 is delivered, e.g., to
fill the puncture 90. Alternatively, the delivery sheath 20
may not include a side port, and a separate injection sheath
(not shown) may be used to deliver the sealing material 99.
In this alternative, the delivery sheath 20 may be removed
after delivering the sealing member 10, and the injection

sheath may be advanced over the filament 12 into the puncture 90 to deliver the sealing material.

In another alternative, injection of the hydrogel precursor mixture into the lumen 26 of the delivery sheath 20 may be used to force the sealing member 10 out of the lumen 20, i.e., to initially deploy the sealing member 10 into the vessel 94. After the sealing member 10 has been ejected from the delivery sheath 20 into the vessel 94 in this manner, further hydrogel precursor mixture delivery may be discontinued, until the sealing member 10 is retracted against the wall of the vessel 94.

5

10

15

In further alternatives, the pusher member 30 may be used to deliver the sealing material 99 into the puncture, e.g., via lumen 36.

Once the sealing member 10 has been deployed within the vessel 94, the sealing member 10 may begin to be absorbed rapidly, e.g., due to exposure to blood within the vessel 94. As explained above, the sealing member 10 may dissolve within not more than about twenty-four (24) hours after deployment. In one embodiment, the filament 12 may also be formed from 20 bioabsorbable material, although the filament material may be absorbed over a longer period of time, e.g., greater than about twenty-four (24) hours after exposure within the patient's body. Similarly, the extravascular sealing material 99 may also be bioabsorbable, e.g., at a rate substantially 25 slower than the sealing member 10.

In an alternative embodiment of the invention, if the filament is not bioabsorbable, the filament 12 may be removed, e.g., by pulling the filament 12 out of the patient's body after sufficient time for the sealing member 10 to dissolve. For example, the proximal end 12a may be released, if secured to the patient's skin 92, and pulled through the extravascular sealing material 99 and out of the puncture 90. Thus, the filament 12 may remain until hemostasis has been substantially established and/or after the sealing member 10 has been substantially absorbed. In this regard, the filament 12 may be removed at the time of patient ambulation, e.g., before discharge from the medical facility, or even subsequently during a follow-up visit. In this embodiment, the filament 12 may have a sufficiently small diameter or other cross-section so that the small tract resulting from its removal does not bleed or otherwise leak substantially. Any bleeding or leaking may be managed, e.g., by compression for a short period of time or a compressive bandage (not shown).

10

15

#### CLAIMS

1. A device for sealing a puncture extending through tissue to a body lumen, comprising:

an elongate retaining member comprising a proximal end

and a distal end sufficiently small to be directed through the

puncture

a sealing member on the distal end of the retaining member, the sealing member comprising bioabsorbable material that is substantially absorbed within about twenty-four hours of exposure to an aqueous physiological environment within the body lumen.

- 2. The device of claim 1, wherein the sealing member is substantially absorbed within about twelve hours of exposure within the body lumen.
- 3. The device of claim 1, wherein the sealing member is substantially absorbed within about three hours of exposure within the body lumen.

20

10

15

- 4. The device of claim 1, wherein the sealing member is substantially absorbed within about one hour of exposure within the body lumen.
- 5. The device of any of claims 1 4, wherein the retaining member comprises bioabsorbable material.

6. The device of claim 5, wherein the retaining member is substantially absorbed after at least about twenty-four hours of exposure within the body lumen.

5

7. The device of any of claims 1 - 4, wherein the retaining member comprises non-bioabsorbable material and a lubricious material on an exterior surface of the retaining member.

10

- 8. The device of any of claims 1 7, wherein the sealing member comprises at least one of a carbohydrate and a salt.
- 9. The device of any of claims 1 8, wherein the sealing member is compressible from a generally planar enlarged condition to a contracted condition to facilitate delivery of the sealing member through the puncture into the body lumen.

20

25

10. The device of claim 9, wherein the sealing member is biased to assume the enlarged condition when released within the body lumen, the enlarged condition defining a cross - section preventing the sealing member from being withdrawn from the body lumen into the puncture.

11. An apparatus device for sealing a puncture extending through tissue into a blood vessel, comprising:

a tubular member comprising a proximal end, a distal end having a size and shape for insertion into the puncture, and a lumen extending between the proximal and distal ends;

5

10

15

a closure device comprising a sealing member and an elongate retaining member, the sealing member formed from a first bioabsorbable material disposed within the lumen of the tubular member, the retaining member comprising a proximal end extending proximally through the lumen to the proximal end of the tubular member and a distal end coupled to the sealing member, and

an extravascular sealing material deliverable into the puncture around the retaining member, the extravascular sealing material comprising a second bioabsorbable material that is absorbed at a slower rate than the first bioabsorbable material when exposed to an aqueous physiological environment.

- 12. The apparatus of claim 11, wherein the first
  20 bioabsorbable material is substantially absorbed within
  twenty-four hours of exposure to an aqueous physiological
  environment within the body lumen.
- 13. The apparatus of claims 11 or 12, wherein the
  25 retaining member comprises a third bioabsorbable material that

is absorbed at a slower rate than the first bioabsorbable material when exposed to an aqueous physiological environment.

- 14. The apparatus of claim 13, wherein the third
  5 bioabsorbable material is substantially absorbed after at
  least about twenty-four hours of exposure within the body
  lumen.
- 15. The apparatus of claim 11, wherein the retaining

  member comprises non-bioabsorbable material and a lubricious

  material on an exterior surface of the retaining member to

  facilitate removal of the retaining member through the

  extravascular sealing material.
- 16. The apparatus of any of claims 11 15, wherein the sealing member comprises at least one of a carbohydrate and a salt that is substantially absorbed within about twenty-four hours of exposure to an aqueous physiological environment within the body lumen.

20

17. The apparatus of any of claims 11 - 16, wherein the sealing member is compressible from a generally planar enlarged condition to a contracted condition to facilitate loading the sealing member into the tubular member.

25

18. The apparatus of any of claims 11 - 17, wherein the sealing member is biased to assume the enlarged condition when released within the body lumen, the enlarged condition defining a cross-section preventing the sealing member from being withdrawn from the body lumen into the puncture.

5

10

15

25

- 19. The apparatus of claim 11, the extravascular sealing material comprising a liquid sealing material, the apparatus further comprising a syringe assembly for delivering a liquid sealing material into the puncture.
- 20. The apparatus of claim 19, wherein the tubular member comprises a side port on the proximal end communicating with the lumen in the tubular member, and wherein the side port communicates with the syringe assembly for delivering the liquid sealing material, via the lumen of the tubular member, into the puncture.
- 21. The apparatus of claim 11, wherein the extravascular 20 material comprises a solid plug deliverable into the puncture.
  - 22. The apparatus of claim 11, further comprising a pusher member disposed within the lumen of the tubular member proximal to the sealing member, the pusher member being slidable axially relative to the tubular member for deploying

the sealing member from the lumen beyond the distal end of the tubular member.





FIG. 1






FIG. 3A




FIG. 3B




FIG. 4




FIG. 5




FIG. 6

## **INTERNATIONAL SEARCH REPORT**

nal Application No PC17US2005/028660

Α.	CLASSIFICATION C A61B1	F SUBJECT	MATTER
	MOTO	. , , , , ,	

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

 $\begin{tabular}{ll} \begin{tabular}{ll} Minimum documentation searched (classification system followed by classification symbols) \\ A61B \end{tabular}$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## EPO-Internal

J. DOCUME	ENTS CONSIDERED TO BE RELEVANT		r
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
Y	US 2004/093025 A1 (EGNELOV PER) 13 May 2004 (2004-05-13) paragraph '0031!; figures		1-10
Y	US 2002/052572 A1 (FRANCO KENNE 2 May 2002 (2002-05-02) paragraph '0053! - paragraph '00 figure 3		1-10
A	US 2001/003158 A1 (KENSEY KENNE 7 June 2001 (2001-06-07) paragraph '0049! - paragraph '0 figures		1-22
A	US 2004/162578 A1 (REDMOND RUSS AL) 19 August 2004 (2004-08-19) abstract; figures	ELL J ET	1–22
X Furth	her documents are listed in the continuation of box C.	Patent family members are listed	in annex.
		<u> </u>	
"A" docume consid "E" earlier of filing d "L" docume which citation "O" docume other i "P" docume later if	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	"T" later document published after the interpretary of the principle of the interpretary of the principle of the invention  "X" document of particular relevance; the cannot be considered novel or canno involve an inventive step when the document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious in the art.  "&" document member of the same patent	the application but seeny underlying the claimed invention to be considered to cournent is taken alone claimed invention eventive step when the ore other such docupus to a person skilled tramily
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report
2	3 December 2005	10/01/2006	
Name and r	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31–70) 340–2040, Tx. 31 651 epo nl,	Authorized officer	
	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2		

# INTERNATIONAL SEARCH REPORT

Intel nal Application No
PCT7US2005/028660

		PCT7US2005/028660
	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	· · · · · · · · · · · · · · · · · · ·
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Ą	US 2001/047187 A1 (MILO CHARLES F ET AL) 29 November 2001 (2001-11-29) figure 22	1-22
i.		

# INTERNATIONAL SEARCH REPORT

mormation on patent family members

Inte nal Application No
PCT/US2005/028660

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 2004093025	A1	13-05-2004	NONE			
US 2002052572	A1	02-05-2002	US	2005004584	A1	06-01-2005
US 2001003158	A1	07-06-2001	NONE			
US 2004162578	A1	19-08-2004	NONE	<b></b>		
US 2001047187	A1	29-11-2001	US US	6899889 2001051813		31-05-2005 13-12-2001